04.04.2012 - After signing a broad licensing deal with Amgen Inc. that involves five experimental compounds, AstraZeneca is looking for partnerships with industry peers.
London/Stockholm – Martin Mackay, head of research at the London-headquartered drugmaker, which conducts its R&D in Sweden, said he was also considering smaller acquisitions, product licensing deals and more partnerships with big biotech and big pharma. The deal with Amgen buys rights to jointly develop and sell five of the US biotech major's experimental autoimmune drugs, and follows a similar tie-up in diabetes five years ago with Bristol-Myers Squibb. Amgen and AstraZeneca decided to jointly develop and commercialise five of Amgen's mAbs in the field of inflammation. The deal includes the anti-IL17R mAb brodalumab which will begin phase III testing this year in psoriasis. The monoclonal antibody is also being tested in phase II to treat psoriatic arthritis and asthma. The shared portfolio also includes: AMG 139, an undisclosed mAb in Phase Ib testing for Crohn's disease, AMG 157, a mAb in phase Ib testing for asthma and atopic dermatitis, AMG 181, an undisclosed mAb in Phase Ib testing for ulcerative colitis and Crohn's disease and finally AMG 557, a mAb in phase I for systemic lupus erythematosus (SLE). Amgen receives $50m upfront. The partners and will share costs and profits. The British-Swedish company will fund two thirds of costs until 2014, after which the partners will split costs equally. Amgen and AstraZeneca will share profits equally. AstraZeneca is in the lead for the development and commercialisation of AMG 139, AMG 157 and AMG 181, while its US partner is responsible for brodalumab and AMG 557. Analysts expect that AstraZeneca alone will invest about $250m in 2013 and 2014. However, the company declined to comment those numbers. The drugmaker is suffering from recent product failure and shrinking revenues. Mackay announced the intention to close other similar deals by the end of the year.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.